Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olmesartan for early atrial fibrillation recurrence after radiofrequency ablation
ChiCTR-IPR-15006367Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of olmesartan in Atrial fibrillation (AFib) (2 arms), sponsored by Tongji Hospital. Primary endpoints: TLR4 expression, MyD88 expression and 1 more. Planned start Jun 2015; status: not yet recruiting.
02
Drugs
olmesartan
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR-IPR-15006367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15006367.